Stipend and Dates
Up to $30,500. for study related time and travel (multiple payments)
|All dates & times are tentative and may change.||Cohort 6|
|Note: This study has (2) 48 hour and (4) 24 hour holter monitor periods during the inhouse stay. NO electronics (cell phones, computers, TV, etc.)|
|Day -1 Admit||May 18, 2023|
|Day 43 Discharge||Jun 30, 2023|
|Day 46 outpatient visit||Jul 03|
|Day 50 outpatient visit||Jul 07|
|Day 57 outpatient visit||Jul 14|
|Day 64 outpatient visit||Jul 21|
|Day 71 outpatient visit||Jul 28|
|Day 78 outpatient visit||Aug 04|
|Day 85 outpatient visit||Aug 11|
|Day 92 outpatient visit||Aug 18|
|Day 99 outpatient visit||Aug 25|
|Day 106 possible outpatient visit - will be determined||Sep 01|
|Day 113 possible outpatient visit - will be determined||Sep 08|
Click here to make an appointment for GI 22805-22805x MAD
Or call 210-225-5437 for more information
Healthy Non-Smoking Males and Females
BMI: 19 to 30 kg/m2
Adequate kidney function (GFR): at least 90 mL/min
Indication: The investigational drug is being studied as a treatment for HIV-1 infection.
Route of Administration: Oral
Washout from previous study: Participants must not be participating in any other study or received an investigational drug within 30 days prior to study dosing for this study.
Contraception requirements for participants assigned Female at Birth and of Childbearing potential
Participants assigned female at birth are considered to be in a postmenopausal state when they are at least 54 years of age with cessation of previously occurring menses for at least 12 months without an alternative cause. In addition, participants assigned female at birth younger than 54 years with amenorrhea of at least 12 months also may be considered postmenopausal if their FSH level is in the postmenopausal range and they are not using hormonal contraception or hormonal replacement therapy. Permanent sterilization includes hysterectomy, bilateral oophorectomy, or bilateral salpingectomy in a participant assigned female at birth of any age. Documentation is required.
The inclusion of participant assigned female at birth and of childbearing potential requires the use of highly effective contraceptive measures with a failure rate of less than 1% per year. They must have a negative serum pregnancy test at screening and a negative pregnancy test at the admission visit before enrollment. Pregnancy tests will be performed at monthly intervals thereafter until the end of contraception requirement.
Participants assigned female at birth and of childbearing potential must agree to 1 of the following contraceptive methods:
Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable method of contraception only when it is in line with the participant’s preferred and usual lifestyle.
Or Consistent and correct use of 1 of the following methods of birth control listed below:
- Hormonal or nonhormonal intrauterine device (IUD)
- Subdermal contraceptive implant
- Bilateral tubal occlusion (upon medical assessment of surgical success)
- Vasectomy in the partner assigned male at birth (upon medical assessment of surgical success)
Or participants assigned female at birth and of childbearing potential who wish to use a hormonally based method must use it in conjunction with a barrier method, preferably a male condom. Hormonal methods are restricted to those associated with the inhibition of ovulation. Hormonally based contraceptives and barrier methods permitted for use in this protocol are as follows:
- Hormonal methods (each method must be used with a barrier method, preferably male condom
- Oral contraceptives (either combined or progesterone only)
- Injectable progesterone
- Transdermal contraceptive patch
- Contraceptive vaginal ring
- Barrier methods (each method must be used with a hormonal method)
- Male condom (with or without spermicide)
- Female condom (with or without spermicide)
- Diaphragm with spermicide
- Cervical cap with spermicide
- Sponge with spermicide
Contraception requirements for participants assigned Male at Birth
A participant assigned male at birth with a partner assigned female at birth and of childbearing potential must use condoms during treatment and until 113 days after the first dose of the study drug. If the partner assigned female at birth and of childbearing potential is not pregnant, additional contraception recommendations should also be considered.
Participants assigned male at birth must also refrain from sperm donation and cryopreservation of sperm cells during treatment and until the end of contraception requirement.
Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (eg, calendar, ovulation, symptothermal, post ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method. A female condom and a male condom should not be used together.
- 8 hours fasting is required for lab work (only water is allowed)
- If taking medications, bring them to your screening appointment
- Bring a valid, non-expired photo ID with you when you attend your screening visit. We accept a government issued identification card such as a driver's license, state issued ID card or passport. You will be required to show this same photo ID at all study visits
- Arrive 30 minutes before your appointment to complete paper work.
- GI 22805-22805x MAD
- Healthy Adults
- NOT CURRENTLY SCREENING
- Male or Female
- Payment amount
- Up to $30,500
- 18 - 45